Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) have been assigned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $43.1429.

Several equities research analysts recently commented on ZBIO shares. Morgan Stanley cut shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $37.00 to $19.00 in a research report on Monday, January 5th. Wedbush reissued an “outperform” rating and issued a $45.00 price target on shares of Zenas BioPharma in a research note on Monday, December 22nd. Citigroup boosted their price target on Zenas BioPharma from $27.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Wall Street Zen cut Zenas BioPharma from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Evercore ISI assumed coverage on Zenas BioPharma in a report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price objective for the company.

Insider Buying and Selling at Zenas BioPharma

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. acquired 50,000 shares of the stock in a transaction dated Wednesday, January 7th. The shares were bought at an average cost of $16.38 per share, for a total transaction of $819,000.00. Following the completion of the acquisition, the chief executive officer directly owned 316,155 shares of the company’s stock, valued at approximately $5,178,618.90. This trade represents a 18.79% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have purchased 100,000 shares of company stock worth $1,639,000. 16.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Quarry LP grew its position in Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Zenas BioPharma during the 3rd quarter worth about $30,000. BNP Paribas Financial Markets boosted its stake in shares of Zenas BioPharma by 120.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after buying an additional 1,716 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Zenas BioPharma by 41.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock valued at $89,000 after acquiring an additional 2,679 shares in the last quarter. Finally, Sei Investments Co. bought a new position in shares of Zenas BioPharma in the 2nd quarter valued at about $118,000.

Zenas BioPharma Price Performance

Shares of ZBIO opened at $16.08 on Friday. The stock has a market cap of $863.17 million, a P/E ratio of -2.27 and a beta of -1.45. Zenas BioPharma has a 1 year low of $5.83 and a 1 year high of $44.60. The stock’s 50-day moving average price is $34.94 and its two-hundred day moving average price is $24.01. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.37.

Zenas BioPharma (NASDAQ:ZBIO) last posted its earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.